Emmyon, Inc. is a privately-held biotechnology corporation. Our expertise is in skeletal muscle biology, metabolism, and small molecule discovery. Our business model is to discover small molecules with beneficial effects for human and animal health, and then commercialize those molecules via out-licensing agreements with consumer-facing companies. We are also involved in R&D collaborations with our commercialization partners.
Emmyon’s portfolio of patent-protected technology includes natural dietary compounds such as ursolic acid and tomatidine, as well as novel compounds. Our natural compounds are being developed as dietary supplements and functional foods that help to maintain normal muscle mass, strength, exercise capacity, healthy metabolism, healthy aging and a non-obese/muscular body composition. Our novel compounds are being developed as pharmaceuticals for muscle atrophy, obesity and type 2 diabetes.
Our technology is positioned to revolutionize industries from pharmaceuticals, nutraceuticals, pet care, production livestock and beyond. We are happy to be collaborating with industry leaders and innovators, from startups to Fortune 500 companies, and we are open to and look forward to further commercialization partnerships.